For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Samumed, LLC

USPTO Granted Patents = 115

% Expired Patents = 2.6

CIPO Patents = 4

EPO Patents = 15

Trademarks = 1

Forward Citations = 2,502

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Sunil Kumar Kc (106 out of 125 patents)

John Hood (96 out of 123 patents)

David Mark Wallace (86 out of 119 patents)

4. Chandramouli Chiruta (53 out of 58 patents)

5. Jianguo Cao (53 out of 84 patents)

6. Gopi Kumar Mittapalli (17 out of 24 patents)

7. Chi Ching Mak (16 out of 34 patents)

8. Venkataiah Bollu (15 out of 26 patents)

9. Charlene F Barroga (13 out of 16 patents)

10. Brian Walter Eastman (13 out of 34 patents)

11. Brian Joseph Hofilena (10 out of 15 patents)

12. Joseph Timothy Marakovits (7 out of 20 patents)

13. Sunil Kumar K C (7 out of 23 patents)

14. Luis A Dellamary (4 out of 77 patents)

15. Yusuf Yazici (3 out of 5 patents)

Core Competencies:

Wnt Signaling

Indazole Inhibitors

Gamma-Diketones

Osteoarthritis Treatment

Carboxamides

Therapeutic Uses

Anti-Inflammatory

Injectable Formulations

115 patents: Sort by Forward Citations

1. 11034682 - Gamma-diketones as wnt/β-catenin signaling pathway activators (2021-06-15),

2. 10981909 - Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide (2021-04-20),

3. 10947228 - Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof (2021-03-16),

4. 10947217 - Isoquinolin-3-YL carboxamides and preparation and use thereof (2021-03-16),

5. 10934297 - 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof (2021-03-02),

6. 10899757 - 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof (2021-01-26),

7. 10882860 - Treatment of osteoarthritis (2021-01-05),

8. 10806726 - Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitors (2020-10-20),

9. 10759799 - Indazole containing macrocycles and therapeutic uses thereof (2020-09-01),

10. 10758523 - Single-dose, ready-to-use injectable formulations (2020-09-01),

11. 10744128 - 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof (2020-08-18),

12. 10703748 - Diazanaphthalen-3-yl carboxamides and preparation and use thereof (2020-07-07),

13. 10669240 - 5-substituted indazole-3-carboxamides and preparation and use thereof (2020-06-02),

14. 10654832 - 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof (2020-05-19),

15. 10653688 - 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof (2020-05-19),

Samumed is a pharmaceutical company focused on advancing regenerative medicine and targeted therapies to address chronic diseases. They utilize their proprietary small molecule platform to develop treatments for conditions such as osteoarthritis, alopecia, degenerative disc disease, and several others. With a commitment to scientific innovation, Samumed aims to revolutionize the field of regenerative medicine and improve patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

115 Patents

#50 in San Diego, CA

#755 in California

#3,339 in US

#6,884 in the World

San Diego, CA, United States of America

Samumed, LLC

Forward Citations = 2,502

19 inventors:

Sunil Kumar Kc (106 out of 125 patents)

John Hood (96 out of 123 patents)

David Mark Wallace (86 out of 119 patents)

4. Chandramouli Chiruta (53 out of 58 patents)

5. Jianguo Cao (53 out of 84 patents)

Please report any incorrect information to [email protected]

Loading…